CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Degarelix +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01731912
NCT01731912N/ACompleted
CompareCT.gov

Degarelix Acetate Prior to Radiation Therapy

University of Washington·interventional·Posted Nov 22, 2012·Updated Jan 18, 2019

In Brief

A clinical study evaluating Degarelix, External Beam Radiation Therapy, and 1 other intervention for Prostate Adenocarcinoma and 4 related conditions. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This pilot clinical trial studies how well degarelix acetate before and during radiation therapy works in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as degarelix acetate, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving degarelix acetate together with radiation therapy may work better in treating prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 22, 2012
Enrollment StartMay 1, 2013
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.6 years ago

Interventions

Degarelixdrug

Given SC

External Beam Radiation Therapyradiation

Undergo standard EBRT

Laboratory Biomarker Analysisother

Correlative studies